Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020
- DOI
- 10.3389/fonc.2022.953013
- Published
- 2022-09-14
- Container
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.3389/fonc.2022.953013,
title = {Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020},
author = {Jeffrey J. Kooijman and Wilhelmina E. van Riel and Jelle Dylus and Martine B. W. Prinsen and Yvonne Grobben and Tessa J. J. de Bitter and Antoon M. van Doornmalen and Janneke J. T. M. Melis and Joost C. M. Uitdehaag and Yugo Narumi and Yusuke Kawase and Jeroen A. D. M. de Roos and Nicole Willemsen-Seegers and Guido J. R. Zaman},
year = {2022},
journal = {Frontiers in Oncology},
doi = {10.3389/fonc.2022.953013},
url = {https://doi.org/10.3389/fonc.2022.953013}
}RIS
TY - JOUR TI - Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020 AU - Jeffrey J. Kooijman AU - Wilhelmina E. van Riel AU - Jelle Dylus AU - Martine B. W. Prinsen AU - Yvonne Grobben AU - Tessa J. J. de Bitter AU - Antoon M. van Doornmalen AU - Janneke J. T. M. Melis AU - Joost C. M. Uitdehaag AU - Yugo Narumi AU - Yusuke Kawase AU - Jeroen A. D. M. de Roos AU - Nicole Willemsen-Seegers AU - Guido J. R. Zaman PY - 2022 JO - Frontiers in Oncology DO - 10.3389/fonc.2022.953013 UR - https://doi.org/10.3389/fonc.2022.953013 ER -
APA
Kooijman, J. J., Riel, W. E. V., Dylus, J., Prinsen, M. B. W., Grobben, Y., Bitter, T. J. J. D., Doornmalen, A. M. V., Melis, J. J. T. M., Uitdehaag, J. C. M., Narumi, Y., Kawase, Y., Roos, J. A. D. M. D., Willemsen-Seegers, N., & Zaman, G. J. R. (2022). Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020. Frontiers in Oncology. https://doi.org/10.3389/fonc.2022.953013
Source records
- crossref · retrieved 2026-09-26T08:42:29.165Z